Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNE-3511
- Development stage
- Discontinued
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GNE-3511 is a potent, selective, orally bioavailable, and central nervous system (CNS)-penetrant small-molecule inhibitor of dual leucine zipper kinase (DLK, also known as MAP3K12). Developed by Genentech, GNE-3511 acts as a stress-activated signaling node inhibitor, blocking the downstream phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun. It has been widely investigated in preclinical models for its neuroprotective effects in neurodegenerative diseases, such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), glaucoma, and neuropathic pain. Additionally, GNE-3511 has been studied for its potential to preserve pancreatic β-cell mass and improve glucose homeostasis in prediabetic and diabetic conditions.
- Other names
- 1496581-76-02-[[6-(3,3-difluoro-1-pyrrolidinyl)-4-[1-(3-oxetanyl)-4-piperidinyl]-2-pyridinyl]amino]-4-pyridinecarbonitrileDLKi-3511DLKi3511DLKi 3511GNE 3511GNE3511GNE-3511
02
Targets
MAP2K4 (Mitogen-activated protein kinase kinase 4)MAP2K7 (Dual specificity mitogen-activated protein kinase kinase 7)MAP3K9 (Mixed lineage kinase 1)MAP3K11 (Mitogen-activated protein kinase kinase kinase 11)MAP3K12 (Mitogen-activated protein kinase kinase kinase 12)
Beyond the preview
Go deeper on GNE-3511.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNE-3511.